Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Anti-neuroinflammatory, protective effects of the synthetic microneurotrophin BNN-20 in the advanced dopaminergic neurodegeneration of "weaver" mice.

Panagiotakopoulou V, Botsakis K, Delis F, Mourtzi T, Tzatzarakis MN, Dimopoulou A, Poulia N, Antoniou K, Stathopoulos GT, Matsokis N, Charalampopoulos I, Gravanis A, Angelatou F.

Neuropharmacology. 2020 Mar 15;165:107919. doi: 10.1016/j.neuropharm.2019.107919. Epub 2019 Dec 23.

PMID:
31877321
2.

Neurosteroids as regulators of neuroinflammation.

Yilmaz C, Karali K, Fodelianaki G, Gravanis A, Chavakis T, Charalampopoulos I, Alexaki VI.

Front Neuroendocrinol. 2019 Oct;55:100788. doi: 10.1016/j.yfrne.2019.100788. Epub 2019 Sep 9. Review.

3.

Effect of topical administration of the microneurotrophin BNN27 in the diabetic rat retina.

Ibán-Arias R, Lisa S, Poulaki S, Mastrodimou N, Charalampopoulos I, Gravanis A, Thermos K.

Graefes Arch Clin Exp Ophthalmol. 2019 Nov;257(11):2429-2436. doi: 10.1007/s00417-019-04460-6. Epub 2019 Sep 12.

PMID:
31512044
4.

The novel dehydroepiandrosterone (DHEA) derivative BNN27 counteracts behavioural deficits induced by the NMDA receptor antagonist ketamine in rats.

Zoupa E, Gravanis A, Pitsikas N.

Neuropharmacology. 2019 Jun;151:74-83. doi: 10.1016/j.neuropharm.2019.04.001. Epub 2019 Apr 5.

PMID:
30959020
5.

Nerve Growth Factor modulates LPS - induced microglial glycolysis and inflammatory responses.

Fodelianaki G, Lansing F, Bhattarai P, Troullinaki M, Zeballos MA, Charalampopoulos I, Gravanis A, Mirtschink P, Chavakis T, Alexaki VI.

Exp Cell Res. 2019 Apr 15;377(1-2):10-16. doi: 10.1016/j.yexcr.2019.02.023. Epub 2019 Feb 25.

6.

Effects of BNN27, a novel C17-spiroepoxy steroid derivative, on experimental retinal detachment-induced photoreceptor cell death.

Tsoka P, Matsumoto H, Maidana DE, Kataoka K, Naoumidi I, Gravanis A, Vavvas DG, Tsilimbaris MK.

Sci Rep. 2018 Jul 13;8(1):10661. doi: 10.1038/s41598-018-28633-1.

7.

Current understanding of the structure and function of family B GPCRs to design novel drugs.

Karageorgos V, Venihaki M, Sakellaris S, Pardalos M, Kontakis G, Matsoukas MT, Gravanis A, Margioris A, Liapakis G.

Hormones (Athens). 2018 Mar;17(1):45-59. doi: 10.1007/s42000-018-0009-5. Epub 2018 Apr 19. Review.

PMID:
29858864
8.

The Synthetic Microneurotrophin BNN27 Affects Retinal Function in Rats With Streptozotocin-Induced Diabetes.

Ibán-Arias R, Lisa S, Mastrodimou N, Kokona D, Koulakis E, Iordanidou P, Kouvarakis A, Fothiadaki M, Papadogkonaki S, Sotiriou A, Katerinopoulos HE, Gravanis A, Charalampopoulos I, Thermos K.

Diabetes. 2018 Feb;67(2):321-333. doi: 10.2337/db17-0391. Epub 2017 Dec 5.

9.

DHEA inhibits acute microglia-mediated inflammation through activation of the TrkA-Akt1/2-CREB-Jmjd3 pathway.

Alexaki VI, Fodelianaki G, Neuwirth A, Mund C, Kourgiantaki A, Ieronimaki E, Lyroni K, Troullinaki M, Fujii C, Kanczkowski W, Ziogas A, Peitzsch M, Grossklaus S, Sönnichsen B, Gravanis A, Bornstein SR, Charalampopoulos I, Tsatsanis C, Chavakis T.

Mol Psychiatry. 2018 Jun;23(6):1410-1420. doi: 10.1038/mp.2017.167. Epub 2017 Sep 12.

PMID:
28894299
10.

The novel synthetic microneurotrophin BNN27 protects mature oligodendrocytes against cuprizone-induced death, through the NGF receptor TrkA.

Bonetto G, Charalampopoulos I, Gravanis A, Karagogeos D.

Glia. 2017 Aug;65(8):1376-1394. doi: 10.1002/glia.23170. Epub 2017 Jun 1.

PMID:
28567989
11.

BNN-20, a synthetic microneurotrophin, strongly protects dopaminergic neurons in the "weaver" mouse, a genetic model of dopamine-denervation, acting through the TrkB neurotrophin receptor.

Botsakis K, Mourtzi T, Panagiotakopoulou V, Vreka M, Stathopoulos GT, Pediaditakis I, Charalampopoulos I, Gravanis A, Delis F, Antoniou K, Zisimopoulos D, Georgiou CD, Panagopoulos NT, Matsokis N, Angelatou F.

Neuropharmacology. 2017 Jul 15;121:140-157. doi: 10.1016/j.neuropharm.2017.04.043. Epub 2017 Apr 28.

PMID:
28461162
12.

The novel dehydroepiandrosterone (DHEA) derivative BNN27 counteracts delay-dependent and scopolamine-induced recognition memory deficits in rats.

Pitsikas N, Gravanis A.

Neurobiol Learn Mem. 2017 Apr;140:145-153. doi: 10.1016/j.nlm.2017.03.004. Epub 2017 Mar 6.

PMID:
28274826
13.

The Multi-faceted Profile of Corticotropin-releasing Factor (CRF) Family of Neuropeptides and of their Receptors on the Paracrine/Local Regulation of the Inflammatory Response.

Dermitzaki E, Venihaki M, Tsatsanis C, Gravanis A, Avgoustinaki PD, Liapakis G, Margioris AN.

Curr Mol Pharmacol. 2018;11(1):39-50. doi: 10.2174/1874467210666170109164430. Review.

PMID:
28103784
14.

Synthetic microneurotrophins in therapeutics of neurodegeneration.

Gravanis A, Pediaditakis I, Charalampopoulos I.

Oncotarget. 2017 Feb 7;8(6):9005-9006. doi: 10.18632/oncotarget.14667. No abstract available.

15.

BNN27, a 17-Spiroepoxy Steroid Derivative, Interacts With and Activates p75 Neurotrophin Receptor, Rescuing Cerebellar Granule Neurons from Apoptosis.

Pediaditakis I, Kourgiantaki A, Prousis KC, Potamitis C, Xanthopoulos KP, Zervou M, Calogeropoulou T, Charalampopoulos I, Gravanis A.

Front Pharmacol. 2016 Dec 26;7:512. doi: 10.3389/fphar.2016.00512. eCollection 2016.

16.

MicroNeurotrophins Improve Survival in Motor Neuron-Astrocyte Co-Cultures but Do Not Improve Disease Phenotypes in a Mutant SOD1 Mouse Model of Amyotrophic Lateral Sclerosis.

Glajch KE, Ferraiuolo L, Mueller KA, Stopford MJ, Prabhkar V, Gravanis A, Shaw PJ, Sadri-Vakili G.

PLoS One. 2016 Oct 7;11(10):e0164103. doi: 10.1371/journal.pone.0164103. eCollection 2016.

17.

Selective and differential interactions of BNN27, a novel C17-spiroepoxy steroid derivative, with TrkA receptors, regulating neuronal survival and differentiation.

Pediaditakis I, Efstathopoulos P, Prousis KC, Zervou M, Arévalo JC, Alexaki VI, Nikoletopoulou V, Karagianni E, Potamitis C, Tavernarakis N, Chavakis T, Margioris AN, Venihaki M, Calogeropoulou T, Charalampopoulos I, Gravanis A.

Neuropharmacology. 2016 Dec;111:266-282. doi: 10.1016/j.neuropharm.2016.09.007. Epub 2016 Sep 9.

PMID:
27618740
18.

Fingolimod induces neurogenesis in adult mouse hippocampus and improves contextual fear memory.

Efstathopoulos P, Kourgiantaki A, Karali K, Sidiropoulou K, Margioris AN, Gravanis A, Charalampopoulos I.

Transl Psychiatry. 2015 Nov 24;5:e685. doi: 10.1038/tp.2015.179.

19.

Application of multispectral imaging detects areas with neuronal myelin loss, without tissue labelling.

Vazgiouraki E, Papadakis VM, Efstathopoulos P, Lazaridis I, Charalampopoulos I, Fotakis C, Gravanis A.

Microscopy (Oxf). 2016 Apr;65(2):109-18. doi: 10.1093/jmicro/dfv349. Epub 2015 Oct 28.

PMID:
26510556
20.

Data in support on the shape of Schwann cells and sympathetic neurons onto microconically structured silicon surfaces.

Simitzi C, Efstathopoulos P, Kourgiantaki A, Ranella A, Charalampopoulos I, Fotakis C, Αthanassakis Ι, Stratakis E, Gravanis A.

Data Brief. 2015 Jul 31;4:636-40. doi: 10.1016/j.dib.2015.07.030. eCollection 2015 Sep.

21.

Laser fabricated discontinuous anisotropic microconical substrates as a new model scaffold to control the directionality of neuronal network outgrowth.

Simitzi C, Efstathopoulos P, Kourgiantaki A, Ranella A, Charalampopoulos I, Fotakis C, Athanassakis I, Stratakis E, Gravanis A.

Biomaterials. 2015 Oct;67:115-28. doi: 10.1016/j.biomaterials.2015.07.008. Epub 2015 Jul 13.

PMID:
26210178
22.

Effects of novel synthetic microneurotrophins in diabetic retinopathy.

Lisa S, Iban-Arias R, Kokona D, Charalampopoulos I, Gravanis A, Thermos K.

Springerplus. 2015 Jun 12;4(Suppl 1):L25. doi: 10.1186/2193-1801-4-S1-L25. eCollection 2015. No abstract available.

23.

Dehydroepiandrosterone: an ancestral ligand of neurotrophin receptors.

Pediaditakis I, Iliopoulos I, Theologidis I, Delivanoglou N, Margioris AN, Charalampopoulos I, Gravanis A.

Endocrinology. 2015 Jan;156(1):16-23. doi: 10.1210/en.2014-1596.

PMID:
25330101
24.

The actin cytoskeleton in rapid steroid hormone actions.

Stournaras C, Gravanis A, Margioris AN, Lang F.

Cytoskeleton (Hoboken). 2014 May;71(5):285-93. doi: 10.1002/cm.21172. Epub 2014 Mar 25. Review.

PMID:
24616288
25.

Differential effects of dehydroepiandrosterone and testosterone in prostate and colon cancer cell apoptosis: the role of nerve growth factor (NGF) receptors.

Anagnostopoulou V, Pediaditakis I, Alkahtani S, Alarifi SA, Schmidt EM, Lang F, Gravanis A, Charalampopoulos I, Stournaras C.

Endocrinology. 2013 Jul;154(7):2446-56. doi: 10.1210/en.2012-2249. Epub 2013 May 21.

PMID:
23696568
26.

Genetic dissection of neurotrophin signaling through the p75 neurotrophin receptor.

Charalampopoulos I, Vicario A, Pediaditakis I, Gravanis A, Simi A, Ibáñez CF.

Cell Rep. 2012 Dec 27;2(6):1563-70. doi: 10.1016/j.celrep.2012.11.009. Epub 2012 Dec 20.

27.

Neurosteroids and microneurotrophins signal through NGF receptors to induce prosurvival signaling in neuronal cells.

Gravanis A, Calogeropoulou T, Panoutsakopoulou V, Thermos K, Neophytou C, Charalampopoulos I.

Sci Signal. 2012 Oct 16;5(246):pt8. doi: 10.1126/scisignal.2003387.

PMID:
23074265
28.

APRIL binding to BCMA activates a JNK2-FOXO3-GADD45 pathway and induces a G2/M cell growth arrest in liver cells.

Notas G, Alexaki VI, Kampa M, Pelekanou V, Charalampopoulos I, Sabour-Alaoui S, Pediaditakis I, Dessirier V, Gravanis A, Stathopoulos EN, Tsapis A, Castanas E.

J Immunol. 2012 Nov 15;189(10):4748-58. doi: 10.4049/jimmunol.1102891. Epub 2012 Oct 15.

29.

The neurosteroid dehydroepiandrosterone (DHEA) protects the retina from AMPA-induced excitotoxicity: NGF TrkA receptor involvement.

Kokona D, Charalampopoulos I, Pediaditakis I, Gravanis A, Thermos K.

Neuropharmacology. 2012 Apr;62(5-6):2106-17. doi: 10.1016/j.neuropharm.2012.01.006. Epub 2012 Jan 17.

PMID:
22269901
30.

The 'self-plagiarism' oxymoron: can one steal from oneself?

Chrousos GP, Kalantaridou SN, Margioris AN, Gravanis A.

Eur J Clin Invest. 2012 Mar;42(3):231-2. doi: 10.1111/j.1365-2362.2012.02645.x. Epub 2012 Jan 24. No abstract available.

PMID:
22268677
31.

Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease.

Ioannou M, Alissafi T, Lazaridis I, Deraos G, Matsoukas J, Gravanis A, Mastorodemos V, Plaitakis A, Sharpe A, Boumpas D, Verginis P.

J Immunol. 2012 Feb 1;188(3):1136-46. doi: 10.4049/jimmunol.1101816. Epub 2011 Dec 30. Erratum in: J Immunol. 2014 Feb 1;192(3):1334.

32.

A novel role of peripheral corticotropin-releasing hormone (CRH) on dermal fibroblasts.

Rassouli O, Liapakis G, Lazaridis I, Sakellaris G, Gkountelias K, Gravanis A, Margioris AN, Karalis KP, Venihaki M.

PLoS One. 2011;6(7):e21654. doi: 10.1371/journal.pone.0021654. Epub 2011 Jul 13.

33.

The calcineurin-nuclear factor of activated T cells signaling pathway mediates the effect of corticotropin releasing factor and urocortins on catecholamine synthesis.

Dermitzaki E, Tsatsanis C, Gravanis A, Margioris AN.

J Cell Physiol. 2012 May;227(5):1861-72. doi: 10.1002/jcp.22914.

PMID:
21702050
34.

Neurosteroid dehydroepiandrosterone interacts with nerve growth factor (NGF) receptors, preventing neuronal apoptosis.

Lazaridis I, Charalampopoulos I, Alexaki VI, Avlonitis N, Pediaditakis I, Efstathopoulos P, Calogeropoulou T, Castanas E, Gravanis A.

PLoS Biol. 2011 Apr;9(4):e1001051. doi: 10.1371/journal.pbio.1001051. Epub 2011 Apr 26.

35.

Matrix metalloproteinase-9 participates in NGF-induced α-secretase cleavage of amyloid-β protein precursor in PC12 cells.

Fragkouli A, Tzinia AK, Charalampopoulos I, Gravanis A, Tsilibary EC.

J Alzheimers Dis. 2011;24(4):705-19. doi: 10.3233/JAD-2011-101893.

PMID:
21321391
36.

Novel dehydroepiandrosterone derivatives with antiapoptotic, neuroprotective activity.

Calogeropoulou T, Avlonitis N, Minas V, Alexi X, Pantzou A, Charalampopoulos I, Zervou M, Vergou V, Katsanou ES, Lazaridis I, Alexis MN, Gravanis A.

J Med Chem. 2009 Nov 12;52(21):6569-87. doi: 10.1021/jm900468p.

PMID:
19845386
37.

Dehydroepiandrosterone protects human keratinocytes against apoptosis through membrane binding sites.

Alexaki VI, Charalampopoulos I, Panayotopoulou M, Kampa M, Gravanis A, Castanas E.

Exp Cell Res. 2009 Aug 1;315(13):2275-83. doi: 10.1016/j.yexcr.2009.04.006. Epub 2009 Apr 18.

PMID:
19379733
38.

Visual genotyping of SNPs of drug-metabolizing enzymes by tetra-primer PCR coupled with a dry-reagent DNA biosensor.

Toubanaki DK, Christopoulos TK, Ioannou PC, Gravanis A.

Pharmacogenomics. 2009 Mar;10(3):495-504. doi: 10.2217/14622416.10.3.495.

PMID:
19290796
39.

Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding.

Gkountelias K, Tselios T, Venihaki M, Deraos G, Lazaridis I, Rassouli O, Gravanis A, Liapakis G.

Mol Pharmacol. 2009 Apr;75(4):793-800. doi: 10.1124/mol.108.052423. Epub 2009 Jan 5.

PMID:
19124613
40.

Membrane androgen receptor activation triggers down-regulation of PI-3K/Akt/NF-kappaB activity and induces apoptotic responses via Bad, FasL and caspase-3 in DU145 prostate cancer cells.

Papadopoulou N, Charalampopoulos I, Anagnostopoulou V, Konstantinidis G, Föller M, Gravanis A, Alevizopoulos K, Lang F, Stournaras C.

Mol Cancer. 2008 Dec 3;7:88. doi: 10.1186/1476-4598-7-88.

42.

Neurosteroids as modulators of neurogenesis and neuronal survival.

Charalampopoulos I, Remboutsika E, Margioris AN, Gravanis A.

Trends Endocrinol Metab. 2008 Oct;19(8):300-7. doi: 10.1016/j.tem.2008.07.004. Epub 2008 Sep 2. Review.

PMID:
18771935
43.

Rho/ROCK/actin signaling regulates membrane androgen receptor induced apoptosis in prostate cancer cells.

Papadopoulou N, Charalampopoulos I, Alevizopoulos K, Gravanis A, Stournaras C.

Exp Cell Res. 2008 Oct 15;314(17):3162-74. doi: 10.1016/j.yexcr.2008.07.012. Epub 2008 Jul 25.

PMID:
18694745
44.

Dry-reagent disposable biosensor for visual genotyping of single nucleotide polymorphisms by oligonucleotide ligation reaction: application to pharmacogenetic analysis.

Toubanaki DK, Christopoulos TK, Ioannou PC, Gravanis A.

Hum Mutat. 2008 Aug;29(8):1071-8. doi: 10.1002/humu.20774.

PMID:
18470949
45.

Immune function in pregnancy: the role of corticotropin-releasing hormone.

Makrigiannakis A, Gravanis A.

Expert Rev Endocrinol Metab. 2008 May;3(3):315-325. doi: 10.1586/17446651.3.3.315.

PMID:
30754199
46.

Catastrophic antiphospholipid syndrome after severe maxillofacial trauma treated effectively with combined therapy in the intensive care unit. An "imaging" case.

Karakitsos D, Saranteas T, Poularas J, Paramythiotou E, Gravanis A, Karabinis A, Mourouzis K, Brennan PA.

J Trauma. 2009 Jun;66(6):1724-7. doi: 10.1097/01.ta.0000243386.77986.dd. No abstract available.

PMID:
18277295
47.

Rapid genotyping of CYP2D6, CYP2C19 and TPMT polymorphisms by primer extension reaction in a dipstick format.

Litos IK, Emmanouilidou E, Glynou KM, Laios E, Ioannou PC, Christopoulos TK, Kampa M, Castanas E, Gravanis A.

Anal Bioanal Chem. 2007 Nov;389(6):1849-57. Epub 2007 Oct 2.

PMID:
17909762
48.

The corticotropin-releasing factor (CRF) family of peptides as local modulators of adrenal function.

Tsatsanis C, Dermitzaki E, Venihaki M, Chatzaki E, Minas V, Gravanis A, Margioris AN.

Cell Mol Life Sci. 2007 Jul;64(13):1638-55. Review.

PMID:
17453142
49.

Corticotropin-releasing factor (CRF) and the urocortins differentially regulate catecholamine secretion in human and rat adrenals, in a CRF receptor type-specific manner.

Dermitzaki E, Tsatsanis C, Minas V, Chatzaki E, Charalampopoulos I, Venihaki M, Androulidaki A, Lambropoulou M, Spiess J, Michalodimitrakis E, Gravanis A, Margioris AN.

Endocrinology. 2007 Apr;148(4):1524-38. Epub 2006 Dec 28.

PMID:
17194738
50.

Neurosteroids as endogenous inhibitors of neuronal cell apoptosis in aging.

Charalampopoulos I, Alexaki VI, Tsatsanis C, Minas V, Dermitzaki E, Lasaridis I, Vardouli L, Stournaras C, Margioris AN, Castanas E, Gravanis A.

Ann N Y Acad Sci. 2006 Nov;1088:139-52. Review.

PMID:
17192562

Supplemental Content

Loading ...
Support Center